# Pahr Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pahr-therapeutics

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.pahrtx.com/
- Total disclosed funding: $4.7M
- Latest round: Seed (Feb 27, 2025)
- Investors on record: 3

## About

Pahr Therapeutics, Inc. is a US-based clinical-stage biotechnology company focused on developing innovative treatments for pulmonary arterial hypertension (PAH), addressing critical unmet medical needs in the healthcare sector.Founded in 2025, Pahr Therapeutics, Inc. specializes in creating therapies for pulmonary arterial hypertension (PAH). The company operates out of Boston, US, and has successfully raised USD 14.00 mn in Seed funding as of July 29, 2025, with investors including RA Capital Management, AN Venture Partners, and The University of Tokyo Edge Capital Partners. The founder's history is not specified, and no mention of subsidiaries or other companies has been provided.Pahr Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative treatments for pulmonary arterial hypertension (PAH). The firm focuses on creating novel mechanisms that target the underlying pathophysiology of PAH, aiming to offer more effective therapeutic options for patients. Their flagship products are designed to improve hemodynamics and exercise capacity in individuals suffering from this debilitating condition. Pahr Therapeutics primarily serves healthcare providers, hospitals, and specialty pharmacies within the North American and European markets, targeting both clinicians and patients who require advanced treatments for PAH. The company’s commitment to addressing unmet medical needs in this space positions it as a significant player in the evolving landscape of pulmonary care.The revenue model for Pahr Therapeutics is centered around partnerships with healthcare providers and institutions involved in the treatment of PAH. Transactions typically occur through collaborations with hospitals and specialty pharmacies, which may involve research agreements or licensing arrangements for their proprietary therapies. These partnerships facilitate the distribution of their therapeutic products directly to healthcare providers, ensuring that patients have access to cutting-edge treatments. Revenue generation is bolstered by the sale of their core products, with pricing structures reflecting the specialized nature of these innovative therapies. The company’s focus on developing effective treatment options establishes a strong foundation for building valuable relationships within the healthcare ecosystem, ultimately driving patient access and adherence to therapy.In July 2025, Pahr Therapeutics, Inc. raised USD 14.00 mn in Seed funding, which will be directed towards the development of treatments for Pulmonary Arterial Hypertension. The company aims to expand its product offerings and enter new markets, particularly targeting regions beyond North America and Europe. Plans for upcoming product launches are set for the next few years, aligning with the company's strategy to address global healthcare needs in PAH management.

## Funding rounds

- Seed, Feb 27, 2025, $4.7M — University of Tokyo Edge Capital Partners, RA Capital Management, AN Ventures Partners

## Investors

- University of Tokyo Edge Capital Partners (https://capitalatlas.ai/funds/university-of-tokyo-edge-capital-partners) — Seed
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Seed
- AN Ventures Partners — Seed